The cannabis plant contains a range of different cannabinoids all of which are understood to have many potential benefits, although some have been further researched than others i.e. CBD (cannabidiol) and THC (Tetrahydrocannabinol). They are said to be effective in pain management from pain symptoms such as multiple sclerosis, acute pain, cancer pain and nausea and vomiting as well as other conditions too. Although with many claims regarding cannabis based treatments much more research is needed before definitive guidelines and recommendations can be given.
Cannabinoids are found in three forms which are synthetic (created in a lab), endogenous (created from within animals/humans) and phyto (plant based). Synthetic relates to a now illegal form of cannabinoid which is only used in lab testing but it was responsible for fatalities when used to by base legislation regarding controlled cannabinoids such as THC which came from plants.
Here is the full scientific article if you wish to download it.
Endogenous cannabinoids are as mentioned from within us we create them ourselves and they do their jobs within our endocannabinoid system, communicating and interacting with cannabinoid (CB) receptors within our bodies. Phytocannabinoids do just the same as the endogenous cannabinoids however in some ases they can be more powerful and useful as they can be administered in different concentrations and dosages.
The two most dominant and widely researched cannabinoids are CBD and THC, mentioned above. CBD is known to have a lot of potential for treating a wide range of conditions as is THC however it provides psychoactive side effect attributed with getting “high”.
Cannabinoids have a therapeutic potential no doubt, however they are yet to be studied in depth to meet the many theories that have been put forward by both researcher and anecdotal user. This paper delves deeper into how the potential of cannabinoids could be used as a cure for types of chronic pain by targeting the cannabinoid 2 receptor (CB2).
Availability of specific pharmacological apparatus allows a massive push of current understanding of cannabinoid receptor 2 role in pathophysiology. Being specific, cannabinoid 2 receptor has surfaced as an intriguing target for chronic pain therapeutic as seen by numerous studies on inflammatory and brain preclinical pain experiments. The actions at the foundation of cannabinoid 2 receptor controlled therapeutic effects are still controversial but results are pointing out on two primary roads: an impact on inflammatory cells and/or an method on nociceptors and spinal cord relay points.
In this study, the researchers will go on to portray the second messenger pathways triggered by cannabinoid receptor 2 agonists, the results underpinning the therapeutic face of cannabinoid receptor 2 specific agonists and the actions invoked to describe their therapeutic action.
Numerous jolts of reports lend a hand to the therapeutic plausibility of cannabinoid 2 receptor agonists in preclinical experiments of chronic inflammatory and neuropathic pain. Nevertheless there is still an envelope of open questions that would be detrimental to look at in order to fully know the real property of this target.
Most chemicals are less specific in rat than in human and functional assays suggest that chemicals effectiveness could be quite variant at rat and human cannabinoid receptor 2. Overall, the puzzle of cannabinoids treating selective pain is not quite put together yet but this study illustrates some vital information into the instructions in how this puzzle might just be completed.